SLC5A2 and heart failure: A meta-study has reported that among individuals diagnosed with heart failure characterized by reduced ejection fraction, the associations remained consistent irrespective of their diabetic condition, SGLT2 inhibition could reduce the combined risk of cardiovascular death or hospitalisation (22).